In a 17-year-old male with a recent seizure disorder treated with brivaracetam and divalproex sodium for six weeks, who now has eosinophilia (33% of leukocytes, absolute count >3,000/µL) without signs of hypersensitivity and with a normal brain MRI, what are the appropriate management steps?

Management of Drug-Induced Eosinophilia in a 17-Year-Old on Antiepileptic Therapy

Immediately discontinue divalproex sodium, as this is most likely drug-induced eosinophilia potentially representing early DRESS syndrome, and continue brivaracetam monotherapy for seizure control.

Immediate Assessment and Action

The absolute eosinophil count >3,000/µL with 33% eosinophilia after 6 weeks of antiepileptic drug (AED) therapy strongly suggests drug-induced eosinophilia, most likely from divalproex sodium. While the patient currently lacks overt hypersensitivity signs, this presentation falls within the typical 2-6 week window for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome 1, 2, 3.

Critical First Steps:

1. Stop the offending medication immediately - Divalproex is the more likely culprit given:

   • Valproate is documented to cause DRESS syndrome 1
   • The FDA label for divalproex lists allergic hypersensitivity reactions with eosinophilia as a serious adverse effect 4
   • Brivaracetam has a superior safety profile with minimal reported eosinophilia 5

2. Assess for end-organ involvement NOW:

   • Liver function tests (AST, ALT, bilirubin) - hepatotoxicity is the most common systemic manifestation 1, 3
   • Cardiac evaluation (troponin, ECG, echocardiogram if troponin elevated) - cardiac involvement can be fatal 3, 6
   • Renal function (creatinine, BUN)
   • Complete blood count - check for atypical lymphocytes, thrombocytopenia
   • Chest X-ray - pulmonary infiltrates may occur

Diagnostic Workup

Rule Out Other Causes (in parallel with drug discontinuation):

Infectious causes (though less likely given normal MRI and no travel history):

• Stool examination for ova and parasites (3 samples)
• Strongyloides serology (critical given potential for hyperinfection if immunosuppressed later) 7
• HIV testing
• Consider helminth serology only if travel history to endemic areas 7

Non-infectious causes:

• Review for new allergies, asthma exacerbations
• Assess for autoimmune markers if systemic symptoms develop
• The UK guideline 7 notes that in non-endemic areas, drugs and allergies are the most common causes of eosinophilia

Treatment Algorithm

If NO End-Organ Damage:

1. Discontinue divalproex immediately
2. Continue brivaracetam monotherapy - adjust dose if needed for seizure control (brivaracetam has excellent tolerability and minimal drug interactions 5)
3. Monitor eosinophil count weekly until normalizing
4. Close clinical surveillance for development of:
   • Rash (morbilliform, facial edema)
   • Fever
   • Lymphadenopathy
   • Jaundice
   • Dyspnea

If End-Organ Damage Present:

1. Hospitalize immediately
2. Discontinue divalproex
3. Initiate systemic corticosteroids (prednisone 0.5-1 mg/kg/day) - this is standard DRESS management 1, 3
4. Hepatoprotection is priority if liver involvement 3
5. Consider ICU admission if cardiac or neurological involvement 6

Seizure Management During Transition

• Do NOT abruptly stop divalproex without ensuring adequate alternative coverage, as the FDA label warns of status epilepticus risk 4
• Optimize brivaracetam dosing first (can load up to 400mg IV if needed, then maintain 80-400mg/day divided) 8
• Taper divalproex over 1-2 weeks while monitoring seizure frequency, unless severe DRESS develops (then stop immediately and accept seizure risk with close monitoring)

Follow-Up Monitoring

• Weekly CBC with differential until eosinophil count normalizes (typically 2-4 weeks after drug discontinuation)
• Liver function tests weekly for 4 weeks
• If eosinophilia persists >3 months after drug discontinuation with levels ≥1.5 × 10⁹/L, refer to hematology to exclude idiopathic hypereosinophilic syndrome 7

Critical Pitfalls to Avoid

1. Do not wait for rash or fever - eosinophilia may precede other DRESS manifestations by days to weeks
2. Do not rechallenge with divalproex - cross-reactivity with other aromatic AEDs (phenytoin, carbamazepine, oxcarbazepine) is common; avoid these permanently 1, 2
3. Do not assume "no hypersensitivity" means benign - DRESS can evolve rapidly with mortality up to 10% if unrecognized 2
4. Do not empirically treat for helminths without travel history or positive testing - this is drug-induced until proven otherwise

Alternative AED Selection

If brivaracetam monotherapy proves inadequate:

• Levetiracetam (structurally related to brivaracetam but may be tried cautiously)
• Lamotrigine (with slow titration)
• Lacosamide
• Avoid all aromatic AEDs permanently (phenytoin, carbamazepine, oxcarbazepine, phenobarbital)

The key principle: drug discontinuation is both diagnostic and therapeutic - if eosinophilia resolves within 2-4 weeks, this confirms drug causation and prevents progression to life-threatening DRESS syndrome.